Open Payments

TAREK I HASSANEIN

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology
Where
CORONADO, CA
NPI
1801854450
Received
$339,116 in 375 records, 2019 to 2025 ($278,106 general, $61,009 research)
As principal investigator
$5,224,548 of research payments to others in 1,661 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment54$48,957
2024General payment66$48,036
2023General payment25$39,360
2022General payment53$35,063
2021General payment32$14,699
2021Research payment1$69
2020General payment26$14,913
2020Research payment1$6,000
2019General payment88$77,075
2019Research payment29$54,939

By company

CompanyRecordsAmountYears
ABBVIE INC.133$104,2542019–2025
Gilead Sciences, Inc.67$76,1542019–2025
Bausch Health US, LLC27$41,8022019
Madrigal Pharmaceuticals34$33,1392024–2025
Mallinckrodt Hospital Products Inc.13$28,3242020–2023
Eli Lilly and Company3$19,1372019–2020
Shionogi Inc9$8,5362019–2020
Grifols Biologicals LLC5$5,5732019
Mallinckrodt Enterprises LLC4$3,5212019
Merit Medical Systems Inc1$3,3802025
GlaxoSmithKline, LLC.1$3,2002025
Baxter Healthcare2$2,1702019–2021
HISTOSONICS, INC.7$2,0782024–2025
Grifols Therapeutics LLC1$2,0502023
Eisai Inc.5$1,4262021–2023
Kowa Research Institute, Inc.2$1,3002024
Intercept Pharmaceuticals, Inc.3$8662019–2021
Ipsen Bioscience Inc.1$4852024
Allergan, Inc.11$2252019–2020
Grifols Shared Services North America, Inc.2$2102022–2025
Janssen Biotech, Inc.2$1982021–2022
Boston Scientific Corporation2$1702022
Grifols, S.A.1$1182022
Ortho Dermatologics, a division of Bausch Health US, LLC1$1172023
Provepharm Inc.1$692021
BIOTRONIK INC.1$692022
Intra-Sana Laboratories1$642021
Inspire Medical Systems, Inc.1$512025
Travere Therapeutics, Inc.19$492019–2022
Boehringer Ingelheim Pharmaceuticals, Inc.1$472025
NESTLE HEALTHCARE NUTRITION INC.2$452021
Celgene Corporation3$432022–2023
Amgen Inc.1$342022
Astellas Pharma US Inc1$342025
AstraZeneca Pharmaceuticals LP1$322025
Lilly USA, LLC1$312025
Genentech USA, Inc.1$242022
Novo Nordisk Inc1$232019
Phathom Pharmaceuticals, Inc.1$192024
Shire North American Group Inc1$152019
Salix Pharmaceuticals, a division of Bausch Health US, LLC1$122020

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v56$188,917
Research payment31$61,009
Consulting Fee14$43,848
Travel and Lodging49$25,626
Food and Beverage197$12,016
Debt forgiveness1$3,380
Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing1$3,250
Honoraria1$750
Education25$318

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-09Madrigal Pharmaceuticals$9Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-12-01GlaxoSmithKline, LLC.$3,200Consulting FeeCash or cash equivalent2025
2025-11-26Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLivdelzi Drug, INFLAM2025
2025-11-19Gilead Sciences, Inc.$130Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2025
2025-11-13Boehringer Ingelheim Pharmaceuticals, Inc.$47Food and BeverageIn-kind items and services2025
2025-11-13ABBVIE INC.$16Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-11-12Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-11-10Gilead Sciences, Inc.$35Food and BeverageIn-kind items and services2025
2025-11-09Grifols Shared Services North America, Inc.$124Food and BeverageIn-kind items and servicesAlbutein Biological, Critical Care Medicine2025
2025-11-09ABBVIE INC.$44Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-11-04Gilead Sciences, Inc.$148Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-10-24Gilead Sciences, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-10-09Madrigal Pharmaceuticals$4,935Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-10-09Madrigal Pharmaceuticals$966Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-10-09Madrigal Pharmaceuticals$146Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-10-08Madrigal Pharmaceuticals$154Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-10-02Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2025
2025-09-30AstraZeneca Pharmaceuticals LP$32Food and BeverageIn-kind items and services2025
2025-09-23Gilead Sciences, Inc.$121Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2025
2025-09-18ABBVIE INC.$16Food and BeverageIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGY2025
2025-09-03Merit Medical Systems Inc$3,380Debt forgivenessCash or cash equivalent2025
2025-09-02ABBVIE INC.$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2025
2025-08-15ABBVIE INC.$34Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-08-07Madrigal Pharmaceuticals$26Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-07-18Madrigal Pharmaceuticals$5,287Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-07-18Madrigal Pharmaceuticals$652Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-07-18Madrigal Pharmaceuticals$244Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-07-18Madrigal Pharmaceuticals$231Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-07-15ABBVIE INC.$127Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-07-15Astellas Pharma US Inc$34Food and BeverageIn-kind items and servicesVeozah Drug, Biological2025
2025-07-11ABBVIE INC.$19Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-09Lilly USA, LLC$31Food and BeverageIn-kind items and servicesMOUNJARO Drug, Diabetes2025
2025-06-27ABBVIE INC.$190Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-06-27ABBVIE INC.$40Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-06-23HISTOSONICS, INC.$940Travel and Lodging (4 payments)Cash or cash equivalent2025
2025-06-05Madrigal Pharmaceuticals$21Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-29ABBVIE INC.$16Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-05-21Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2025
2025-05-21Madrigal Pharmaceuticals$112Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-05-02Madrigal Pharmaceuticals$99Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-23Madrigal Pharmaceuticals$45Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-18ABBVIE INC.$12Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-04-15HISTOSONICS, INC.$133Food and BeverageCash or cash equivalent2025
2025-04-12Madrigal Pharmaceuticals$46Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-10Inspire Medical Systems, Inc.$51Food and BeverageIn-kind items and servicesINSPIRE Device, NEUROLOGY2025
2025-04-08Madrigal Pharmaceuticals$108Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2025-04-03ABBVIE INC.$22Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-03-27ABBVIE INC.$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2025
2025-03-25Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLivdelzi Drug, INFLAM2025
2025-03-18Gilead Sciences, Inc.$109Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2025
2025-03-18ABBVIE INC.$3Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-03-06ABBVIE INC.$16Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-03-04ABBVIE INC.$33Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2025
2025-01-06Madrigal Pharmaceuticals$114Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2025
2024-12-19ABBVIE INC.$11Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-11-26Gilead Sciences, Inc.$3,240Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLivdelzi Drug, INFLAM2024
2024-11-18HISTOSONICS, INC.$98Food and BeverageCash or cash equivalent2024
2024-11-18HISTOSONICS, INC.$31Food and BeverageCash or cash equivalent2024
2024-11-16Gilead Sciences, Inc.$113Food and BeverageIn-kind items and services2024
2024-11-15Madrigal Pharmaceuticals$138Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-11-15Madrigal Pharmaceuticals$114Food and BeverageIn-kind items and servicesRESMETIROM Drug, LIVER DISEASE2024
2024-11-07ABBVIE INC.$15Food and BeverageIn-kind items and servicesLINZESS Drug, GASTROENTEROLOGY2024
2024-11-05ABBVIE INC.$7Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-10-31Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2024
2024-10-29Gilead Sciences, Inc.$113Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2024
2024-10-15ABBVIE INC.$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2024
2024-10-05Ipsen Bioscience Inc.$485Travel and LodgingIn-kind items and services2024
2024-10-03ABBVIE INC.$16Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-09-27Madrigal Pharmaceuticals$4,935Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$520Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$470Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$254Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$226Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$186Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$94Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$80Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-27Madrigal Pharmaceuticals$77Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-25Gilead Sciences, Inc.$4,930Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLivdelzi Drug, INFLAM2024
2024-09-17Gilead Sciences, Inc.$992Travel and LodgingIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-09-17Gilead Sciences, Inc.$118Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-09-17ABBVIE INC.$32Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-09-16Madrigal Pharmaceuticals$4,583Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-16Madrigal Pharmaceuticals$218Travel and LodgingIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-16Madrigal Pharmaceuticals$144Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$3,878Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREZDIFFRA Drug, LIVER DISEASE2024
2024-09-12Madrigal Pharmaceuticals$133Food and BeverageIn-kind items and servicesREZDIFFRA Drug, LIVER DISEASE2024
2024-08-26ABBVIE INC.$5Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-08-24Gilead Sciences, Inc.$776Travel and LodgingIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$376Travel and LodgingIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$253Travel and LodgingIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$142Travel and LodgingIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$59Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$55Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$52Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-24Gilead Sciences, Inc.$36Food and BeverageIn-kind items and servicesLivdelzi Drug, INFLAM2024
2024-08-22ABBVIE INC.$11Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-08-15Gilead Sciences, Inc.$3,790Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2024
2024-08-13Gilead Sciences, Inc.$121Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2024
2024-07-18ABBVIE INC.$21Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-07-16ABBVIE INC.$7Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-07-11ABBVIE INC.$21Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-06-27ABBVIE INC.$13Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-06-21ABBVIE INC.$2,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2024
2024-06-20ABBVIE INC.$19Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-05-28ABBVIE INC.$6Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-05-16ABBVIE INC.$21Food and BeverageIn-kind items and servicesHUMIRA Biological, IMMUNOLOGY2024
2024-05-14ABBVIE INC.$109Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-05-12HISTOSONICS, INC.$166Travel and LodgingCash or cash equivalent2024
2024-05-02ABBVIE INC.$21Food and BeverageIn-kind items and servicesCREON Drug, ENDOCRINOLOGY2024
2024-04-19HISTOSONICS, INC.$676Travel and LodgingCash or cash equivalent2024
2024-04-19HISTOSONICS, INC.$32Travel and LodgingCash or cash equivalent2024
2024-04-18Gilead Sciences, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-16Phathom Pharmaceuticals, Inc.$19Food and BeverageIn-kind items and servicesVOQUEZNA Drug, GASTROENTEROLOGY2024
2024-04-11ABBVIE INC.$24Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-04-03ABBVIE INC.$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2024
2024-03-26ABBVIE INC.$7Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-03-21Kowa Research Institute, Inc.$899Travel and LodgingCash or cash equivalent Drug2024
2024-03-21Kowa Research Institute, Inc.$400Food and BeverageCash or cash equivalent Drug2024
2024-03-12ABBVIE INC.$108Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2024
2024-02-01ABBVIE INC.$22Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2023-11-12Ortho Dermatologics, a division of Bausch Health US, LLC$117Food and BeverageIn-kind items and servicesXIFAXAN Drug, Gastroenterology2023
2023-11-10Gilead Sciences, Inc.$105Food and BeverageIn-kind items and services2023
2023-11-07ABBVIE INC.$3,125Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2023
2023-11-06ABBVIE INC.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2023
2023-11-01ABBVIE INC.$1,107Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-11-01ABBVIE INC.$123Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-10-25ABBVIE INC.$82Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-08-29Mallinckrodt Hospital Products Inc.$5,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTERLIVAZ Drug, CRITICAL CARE2023
2023-08-23Gilead Sciences, Inc.$3,550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-08-22Mallinckrodt Hospital Products Inc.$140Food and BeverageIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2023
2023-08-22Eisai Inc.$29Food and BeverageCash or cash equivalentLenvima Drug, Oncology2023
2023-08-08Gilead Sciences, Inc.$107Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2023
2023-06-19Gilead Sciences, Inc.$1,780Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-05-29Gilead Sciences, Inc.$4,620Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpclusa Drug, HCV2023
2023-05-25Gilead Sciences, Inc.$124Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2023
2023-05-16ABBVIE INC.$124Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-05-15ABBVIE INC.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2023
2023-05-10ABBVIE INC.$987Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-05-10ABBVIE INC.$112Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-03-31ABBVIE INC.$31Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2023
2023-03-07Gilead Sciences, Inc.$72Food and BeverageIn-kind items and services2023
2023-03-02Celgene Corporation$12Food and BeverageCash or cash equivalent2023
2023-02-27Grifols Therapeutics LLC$2,050Consulting FeeCash or cash equivalentAlbutein Biological, Critical Care Medicine2023
2023-02-14Mallinckrodt Hospital Products Inc.$6,890Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTERLIVAZ Drug, CRITICAL CARE2023
2023-02-10Celgene Corporation$13Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2023
2022-12-03Mallinckrodt Hospital Products Inc.$55Food and BeverageIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-12-03Mallinckrodt Hospital Products Inc.$39Food and BeverageIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-12-02Mallinckrodt Hospital Products Inc.$158Travel and LodgingIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-11-30Mallinckrodt Hospital Products Inc.$327Travel and LodgingIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-11-30Mallinckrodt Hospital Products Inc.$318Travel and LodgingIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-11-30Mallinckrodt Hospital Products Inc.$23Travel and LodgingIn-kind items and servicesTERLIVAZ Drug, CRITICAL CARE2022
2022-11-22Amgen Inc.$34Food and BeverageIn-kind items and services2022
2022-11-06Grifols, S.A.$118Food and BeverageIn-kind items and servicesAlbutein Biological, Critical Care Medicine2022
2022-11-05ABBVIE INC.$56Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-11-04Gilead Sciences, Inc.$106Food and BeverageIn-kind items and services2022
2022-10-20ABBVIE INC.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-10-13ABBVIE INC.$904Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-10-13ABBVIE INC.$125Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-09-28ABBVIE INC.$25Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-09-27ABBVIE INC.$124Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-09-13Travere Therapeutics, Inc.$0EducationIn-kind items and servicesCholbam Drug, Hepatology2022
2022-08-25Grifols Shared Services North America, Inc.$85Food and BeverageIn-kind items and servicesProlastin-C Liquid Biological, Pulmonology2022
2022-08-10ABBVIE INC.$1,875Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-08-02ABBVIE INC.$3,125Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-07-26ABBVIE INC.$117Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-07-15Travere Therapeutics, Inc.$1EducationIn-kind items and servicesCholbam Drug, Hepatology2022
2022-07-15Travere Therapeutics, Inc.$0EducationIn-kind items and servicesCholbam Drug, Hepatology2022
2022-06-29Travere Therapeutics, Inc.$6EducationIn-kind items and servicesCholbam Drug, Hepatology2022
2022-06-24ABBVIE INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-06-23Janssen Biotech, Inc.$99EducationIn-kind items and servicesSTELARA Biological, Immunology2022
2022-06-20Mallinckrodt Hospital Products Inc.$5,720Consulting FeeCash or cash equivalent2022
2022-06-20Mallinckrodt Hospital Products Inc.$153Food and BeverageIn-kind items and services2022
2022-06-18ABBVIE INC.$514Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$294Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$65Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$40Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$30Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$30Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-06-18ABBVIE INC.$18Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-05-24Gilead Sciences, Inc.$124Food and BeverageIn-kind items and servicesEpclusa Drug, HCV2022
2022-05-12ABBVIE INC.$21Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2022
2022-05-10Genentech USA, Inc.$24Food and BeverageIn-kind items and servicesTECENTRIQ Biological, BioOncology2022
2022-04-28BIOTRONIK INC.$69Food and BeverageIn-kind items and servicesBIOMONITOR Device, Cardiology/Vascular Diseases2022
2022-04-06Boston Scientific Corporation$119Food and BeverageIn-kind items and servicesWATCHMAN Access System Device, WATCHMAN_IC2022
2022-04-05Boston Scientific Corporation$50Food and BeverageIn-kind items and servicesEMBLEM MRI S-ICD Device, EMBLEM_CRM2022
2022-03-16Eisai Inc.$25Food and BeverageCash or cash equivalentLenvima Drug, Oncology2022
2022-03-16ABBVIE INC.$25Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-03-07ABBVIE INC.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-03-01ABBVIE INC.$769Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-03-01ABBVIE INC.$124Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-02-28ABBVIE INC.$4,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMAVYRET Drug, VIROLOGY2022
2022-02-23ABBVIE INC.$868Travel and LodgingIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-02-23ABBVIE INC.$39Food and BeverageIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2022-01-28Celgene Corporation$16Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2022
2022-01-12ABBVIE INC.$6EducationIn-kind items and servicesMAVYRET Drug, VIROLOGY2022
2021-11-18ABBVIE INC.$17Food and BeverageIn-kind items and servicesHUMIRA Biological, IMMUNOLOGY2021
2021-11-16Mallinckrodt Hospital Products Inc.$4,647Consulting FeeCash or cash equivalent2021

The latest 200 records of 375.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-29Janssen Research & Development, LLCSthrn California Rsrch Ctr$2,226A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-29Janssen Research & Development, LLCSthrn California Rsrch Ctr$3,349A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-22Novo Nordisk ASSOUTHERN CALIFORNIA RESEARCH, LLC$765NN9535-43522025
2025-12-19Regeneron Pharmaceuticals, Inc.Southern California Research Center$1,249A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-12-19Ipsen Bioscience Inc.Southern California Research Center$1,094A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2025
2025-12-19Boehringer Ingelheim International GmbHSouthern California Research Center$3,399Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-12-17Boehringer Ingelheim International GmbHSouthern California Research Center$4A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-12-17Boehringer Ingelheim International GmbHSouthern California Research Center$255A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-12-11Regeneron Pharmaceuticals, Inc.Southern California Research Center$2,144A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-12-11Ipsen Bioscience Inc.Southern California Research Center$44A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho2025
2025-11-27Boehringer Ingelheim International GmbHSouthern California Research Center$1,922A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-27Boehringer Ingelheim International GmbHSouthern California Research Center$3,399Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-11-27Boehringer Ingelheim International GmbHSouthern California Research Center$1,922A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-27Boehringer Ingelheim International GmbHSouthern California Research Center$3,399Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-11-27Boehringer Ingelheim International GmbHSouthern California Research Center$2,655A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-11-25Ipsen Bioscience Inc.Southern California Research Center$1,037A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho2025
2025-11-20Regeneron Pharmaceuticals, Inc.Southern California Research Center$2,709A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-11-14Madrigal PharmaceuticalsSouthern California Research Center$2,070A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-14Madrigal PharmaceuticalsSouthern California Research Center$2,070A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-14Madrigal PharmaceuticalsSouthern California Research Center$2,423A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-11-07Regeneron Pharmaceuticals, Inc.Southern California Research Center$2,498A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-11-06Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-11-06Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-11-06Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-11-05Boehringer Ingelheim International GmbHSouthern California Research Center$3,399Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-11-05Boehringer Ingelheim International GmbHSouthern California Research Center$1,743Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-11-05Boehringer Ingelheim International GmbHSouthern California Research Center$3,500Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-11-04ABBVIE INC.Southern California Research Center$222A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$292A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$99A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$2A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$151A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$2,655A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Janssen Research & Development, LLCSthrn California Rsrch Ctr$3,349A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-10-27Janssen Research & Development, LLCSthrn California Rsrch Ctr$2,226A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-10-27Boehringer Ingelheim International GmbHSouthern California Research Center$252A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-27Janssen Research & Development, LLCSthrn California Rsrch Ctr$2,226A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-10-23Ipsen Bioscience Inc.South Denver Gastroenterology, Pc$665A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2025
2025-10-16Regeneron Pharmaceuticals, Inc.Southern California Research Center$1,249A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-10-09ABBVIE INC.Southern California Research Center$11,847A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,369Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,369Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,369Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,369Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-06Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$652A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$2,280A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$652A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$1,922A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$1,922A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-10-03Boehringer Ingelheim International GmbHSouthern California Research Center$2,280A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-09-26Boehringer Ingelheim International GmbHSouthern California Research Center$3,746Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-26Boehringer Ingelheim International GmbHSouthern California Research Center$1,743Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-26Boehringer Ingelheim International GmbHSouthern California Research Center$1,642Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-26Boehringer Ingelheim International GmbHSouthern California Research Center$1,743Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$79A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$17Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$10Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$10Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$10Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$10Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$43Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$122Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$219Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-09-24Boehringer Ingelheim International GmbHSouthern California Research Center$328A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-09-23Regeneron Pharmaceuticals, Inc.Southern California Research Center$1,249A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-09-19Novo Nordisk ASSOUTHERN CALIFORNIA RESEARCH, LLC$1,665NN9535-43522025
2025-09-18Regeneron Pharmaceuticals, Inc.Southern California Research Center$1,323A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-09-18Ipsen Bioscience Inc.Southern California Research Center$1,711A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho2025
2025-09-17Eli Lilly and CompanySouthern California Research Center$10,000AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT2025
2025-09-12Regeneron Pharmaceuticals, Inc.Southern California Research Center$4,248A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys2025
2025-09-12Ipsen Bioscience Inc.Southern California Research Center$4,015A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf2025
2025-09-04ABBVIE INC.Southern California Research Center$3,000A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy 2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,369Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,754Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,754Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,754Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,431Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03ABBVIE INC.Southern California Research Center$2,077A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod2025
2025-09-03ABBVIE INC.Southern California Research Center$6,145A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$1,754Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-09-03Bausch Health US, LLCSouthern California Research Center$2,352Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$1,642Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$3,500Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$4,262Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$1,743Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$652A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$16,049A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$1,743Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$652A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$3,220A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025
2025-08-28Boehringer Ingelheim International GmbHSouthern California Research Center$16,049A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Diego CountyCoronado city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Coronado, CA, county San Diego County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Coronado, CA
County
San Diego County, CA
State
California
Population B0100319,0153,288,77439,287,377
Population, 2020 census P120,1923,298,63439,538,223
Median age B0100242.037.337.9
Under 18 B0100117.8%20.9%22.0%
65 and over B0100122.1%15.4%15.7%
Households B110017,3031,171,27813,548,091
Foreign born B0500210.1%22.8%27.0%
Median household income B19013$134,534$106,268$99,122
Median family income B19113$166,058$122,377$113,346
Per capita income B19301$81,464$51,976$49,513
Poverty rate B170014.7%10.3%12.0%
Unemployment rate B230254.7%6.1%6.6%
Civilian labor force B230256,8051,689,38420,068,466
Mean commute (minutes) B0801318.125.528.7
Bachelor's degree or higher B1500365.5%43.2%37.1%
Housing units B250019,8961,250,64114,644,735
Owner-occupied B2500354.6%54.6%55.9%
Renters B2500345.4%45.4%44.1%
Median home value B25077$2,000,001$854,700$734,700
Median gross rent B25064$3,257$2,246$2,036
White, not Hispanic B0300267.8%42.4%33.8%
Black B030022.4%4.4%5.2%
Hispanic or Latino B0300220.2%34.6%40.2%
Asian B030023.3%12.1%15.3%
American Indian and Alaska Native B030020.4%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Coronado, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.